Lambda Light Chain Myeloma with Oliguric Cast Nephropathy and Remission with Bortezomib, Doxorubicin and Dexamethasone
Cast nephropathy is one of the major causes of renal failure in patients with multiple myeloma resulting from precipitation of free light chains inside the tubules. Timely diagnosis and treatment confers a better prognosis though around 10% of patients with cast nephropathy remain dialysis dependent...
Main Authors: | R Hada, B Poudyal, A Sharma, R Khatri |
---|---|
Format: | Article |
Language: | English |
Published: |
Nepal Medical Association
2012-12-01
|
Series: | Journal of Nepal Medical Association |
Online Access: | http://jnma.com.np/jnma/index.php/jnma/article/view/378 |
Similar Items
-
Lambda Light Chain Myeloma with Oliguric Cast Nephropathy and Remission with Bortezomib, Doxorubicin and Dexamethasone
by: R Hada, et al.
Published: (2012-12-01) -
Case Report on Renal Failure Reversal in Lambda Chain Multiple Myeloma with Bortezomib and Dexamethasone
by: Bhanu K. Patibandla, et al.
Published: (2014-01-01) -
Treatment of idiopathic light chain deposition disease: complete remission with bortezomib and dexamethasone
by: João Tadeu Damian Souto Filho, et al. -
Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma
by: Kristian T. Andersen, et al.
Published: (2020-01-01) -
Multiagent therapy with pomalidomide, bortezomib, doxorubicin, dexamethasone, and daratumumab (“Pom‐PAD‐Dara”) in relapsed/refractory multiple myeloma
by: Xiang Zhou, et al.
Published: (2020-08-01)